Programs

There are currently no approved therapies for tendinopathy. We’re creating one: TenoMiR®, a one-time injectable for the treatment of lateral epicondylitis (tennis elbow) and the rotator cuff.

Leveraging a novel mechanism of action, TenoMiR® replenishes levels of miR-29a, a molecule that regulates expression of tendinopathy  pathways, to restore tendon structure, relieve pain and improves function in patients, while reducing pain and the need for costly surgeries.

TenoMiR® is leading the race to become the world’s first approved microRNA therapy.

CardioMiR, an anti-miR-92a inhibitor, has the potential to revolutionize heart failure treatment.

Building on Prof. Stefanie Dimmeler’s pioneering work at Goethe University, it targets miR-92a, a key driver of cardiovascular disease. Elevated miR-92a disrupts blood vessel formation, fuels inflammation, and promotes fibrosis in heart failure. Preclinical models show that inhibiting miR-92a improves cardiac function, reduces fibrosis, and counteracts hypertrophy—offering a breakthrough approach to treating heart disease.

We have identified a miRNA that is key to the physical signs of skin aging. This miRNA increases with age and sun exposure reducing the production of proteins that keep skin firm and wrinkle-free.

To reverse the signs of skin aging, we have created DermaMiR™ an inhibitor of this miRNA that, when delivered to skin cells, re-programs them to produce more collagen, elastin and hyaluronic acid, reversing the visible signs of aging. DermaMiR™ will be delivered to the skin via intradermal injection in a similar manner to currently used anti-aging approaches.